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Key messages
What is already known about this subject?
 ► Citrullinated proteins and anti- citrullinated 
protein antibodies forming immune complexes 
belong to the damage- associated molecular 
pattern family, participating in innate immunity 
and are expressed in inflammatory conditions, 
such as in rheumatoid arthritis (RA).
 ► Immune and stromal cells are activated by 
these immune complexes via cellular receptors, 
including toll- like receptor (TLR) 4. NI-0101 is a 
humanised immunoglobulin G1κ monoclonal 
antibody engineered to bind to and block 
the activation of human TLR4, which has 
demonstrated a predictable pharmacokinetics, 
good safety profile and inhibition of in vivo 
lipopolysaccharide- induced cytokine production 
in healthy volunteers.
What does this study add?
 ► We assessed for the first time, in a placebo- 
controlled, double- blind, randomised study, 
the tolerability and efficacy of TLR4 blockade 
in RA patients with inadequate response to 
methotrexate (MTX). Study results indicated 
no significant differences between treatment 
arms for any of the clinical efficacy and 
pharmacodynamics endpoints included in 
prespecified subgroups positive for antibodies 
against selected citrullinated proteins.
How might this impact on clinical practice or 
future developments?
 ► This study demonstrated that the blockage 
of TLR4 is likely not a relevant target in RA 
patients with inadequate response to MTX 
and established disease, its role remains to be 
determined.
 ► Successful targeting of innate immune 
pathways in RA, and potentially also in other 
chronic inflammatory diseases, may require 
broader or earlier inhibitory approaches.
ABSTRACT
Objectives Anti- citrullinated protein antibodies 
(ACPAs) form immune complexes with citrullinated 
proteins binding toll- like receptor (TLR) 4, which has 
been proposed as a mediator of rheumatoid arthritis 
(RA). NI-0101 is a first- in- class humanised monoclonal 
antibody blocking TLR4, as confirmed by inhibition of 
in vivo lipopolysaccharide- induced cytokine release in 
healthy volunteers. This study was design to confirm 
preclinical investigations supporting a biomarker- driven 
approach for treatment of patients with RA who present 
positive for these immune complexes.
Methods Placebo- controlled, double- blind, randomised 
(2:1) trial of the tolerability and efficacy of NI-0101 
(5 mg/kg, every 2 weeks for 12 weeks) versus placebo 
in ACPA- positive RA patients with inadequate response 
to methotrexate. Efficacy measures included Disease 
Activity Score (28- joint count) with C reactive protein 
(DAS28- CRP), European League Against Rheumatism 
(EULAR) good and moderate responses, and American 
College of Rheumatology (ACR) 20, ACR50 and ACR70 
responses. Subgroup analyses defined on biomarkers 
were conducted. Pharmacokinetics, pharmacodynamics 
and safety were reported.
Results 90 patients were randomised (NI-0101 
(61) and placebo (29)); 86 completed the study. No 
significant between- group difference was observed for 
any of the efficacy endpoints. Subgroup analyses using 
baseline parameters as covariants did not reveal any 
population responding to NI-0101. Treatment- emergent 
adverse events occurred in 51.7% of patients who 
received placebo versus 52.5% for NI-0101.
Conclusions We demonstrate for the first time that in 
RA, a human immune- mediated inflammatory disease, 
blocking the TLR4 pathway alone does not improve 
disease parameters. Successful targeting of innate 
immune pathways in RA may require broader and/or 
earlier inhibitory approaches.
INTRODUCTION
Both innate and adaptive immune pathways are 
implicated in the pathogenesis of rheumatoid 
arthritis (RA).1 Anti- citrullinated protein antibodies 
(ACPAs) are characteristic of RA and may be present 
prior to the emergence of clinical symptoms of the 
disease.2 3 Citrullinated proteins and ACPAs form 
immune complexes4 5 which belong to the damage- 
associated molecular pattern (DAMP) family.6 
DAMPs are important regulators of innate inflam-
matory responses. They drive pathogenic processes 
in RA by activating both immune and stromal 
cells by stimulating cellular receptors, including 
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toll- like receptor (TLR) 4.7 8 This pattern recognition receptor 
can be activated by immune complexes formed by citrullinated 
proteins, including matrix- derived molecules (eg, citrullinated- 
fibrinogen) and their associated autoantibodies (ACPAs).9–13 
These molecules are upregulated in some patients with RA and 
are expressed in the synovium.14 Numerous preclinical mech-
anistic studies have shown the potential role for TLR4 and its 
ligands in RA.15–24
Biological agents currently approved for the treatment of RA 
block the actions of tumour necrosis factor (TNF)-α or inter-
leukin (IL)-6 receptor, directly interfere with the actions of T 
cells or deplete B cells.25 T cell inhibition by abatacept and cyto-
kine signalling reduction by Janus kinase inhibitors have also 
demonstrated efficacy for the treatment of RA.26 Numerous 
targeted therapies are available, but unmet needs in the manage-
ment of RA remain. Partial and loss of response are common 
and drug- free remission cannot be achieved in most patients.27 
Moreover, patients who fail one biological agent may receive 
even less benefit when switching to a second agent, even with a 
different mechanism of action.28 This may in part reflect accrual 
of irreversible articular damage mediating chronicity in syno-
vial pathology.28 Some patients ultimately become resistant to 
all currently available therapeutics—so- called difficult- to- treat 
RA,29 requiring new therapeutic solutions. Given the evidence 
supporting a role for TLR4 in RA pathogenesis, we explored 
inhibition of this pathway as a potential treatment target.
NI-0101 is a humanised immunoglobulin (Ig) G1κ mono-
clonal antibody engineered to bind to and block the activation of 
human TLR4. It interferes with TLR4 dimersation, preventing 
signal transduction through the TLR4 cytoplasmic pathway.30 
It has been demonstrated to inhibit the effects of lipopolysac-
charide (LPS) administered to healthy volunteers, which is 
dependent on FcγRII.31 The results from in vitro studies have 
demonstrated a correlation between levels of TLR4 ligands and 
blockade of innate inflammatory responses by NI-0101.9
METHODS
Study design
This was a phase II, proof- of- concept, randomised (2:1), 
placebo- controlled, double blind, international multicentre 
study in patients with moderate- to- severe ACPA- positive RA 
that previously responded inadequately to methotrexate (MTX). 
Patients received addition of NI-0101 (5 mg/kg administered 
every 2 weeks for 12 weeks) or placebo to ongoing MTX treat-
ment for 12 weeks. Patients in both treatment arms were strat-
ified on the basis of FcγRIIa genotype (RR/RH and HH) and C 
reactive protein (CRP) level (above and below 0.7 mg/dL, with a 
maximum of 25% below 0.7 mg/dL). Patients were followed up 
for 12 weeks after NI-0101 was stopped.
Patients
Male and female patients ≥18 years old and with body mass 
indices <30 and >18 kg/m2 with a diagnosis of RA according 
to 2010 American College of Rheumatology (ACR)/European 
League Against Rheumatism (EULAR) criteria, ACPA positive 
and disease duration ≥6 months since formal diagnosis were 
eligible for enrolment. Patients had active RA at screening, 
characterised by ≥6 of 66 swollen joints and ≥6 of 68 tender 
joints, confirmed synovitis in ≥1 of the six swollen joints, CRP 
>0.7 mg/dL or CRP level between 0.3 and 0.7 mg/dL if erythro-
cyte sedimentation rate (ESR) ≥30 mm/hour, and to have been 
receiving MTX for ≥3 months and a stable dose/regimen for ≥6 
weeks prior to screening.
Patient participation was excluded by a history of autoimmune 
disease other than RA, prior receipt of a cytotoxic agent other 
than MTX or immunosuppressive drugs ≤3 months prior to 
screening (see online supplementary data for more details).
Patient and public involvement
It was not appropriate or possible to involve patients or the 
public in the design, or conduct, or reporting or dissemination 
of our research.
Assessments
Efficacy
Efficacy measures included OMERACT RA core outcome set 
and clinical study reported according to EULAR recommen-
dations on conducting/reporting of clinical trials. Efficacy 
measures included mean values and changes from baseline in 
Disease Activity Score including 28- joint count using CRP or 
ESR (DAS28- CRP, DAS28- ESR); Simplified Disease Activity 
Index (SDAI) and Clinical Disease Activity Index (CDAI) scores; 
and proportions of patients achieving EULAR good, moderate 
and no response; or ACR20, ACR50 and ACR70 responses. 
Subgroup analyses included assessment of the effects of baseline 
(study day 0 prior to first treatment administration) patient char-
acteristics and biomarkers (APCA, citrullinated peptide- specific 
APCA, circulating TLR4 ligands, rheumatoid factor (RF)) on 
clinical outcomes.
Pharmacokinetics and pharmacodynamics
NI-0101 concentrations was measured preinfusion, throughout 
the treatment and until the end of the follow- up period. Changes 
from baseline in CRP, IL-6, IL-1β, IL-8, TNF-α and C- X- C motif 
chemokine 10 (CXCL10) were evaluated.
Safety
Safety assessments consisted of recording of adverse events 
(AEs), clinical laboratory values and vital signs; and testing for 
the presence of antidrug antibodies (ADAs).
Statistical analysis
Study populations included the intent- to- treat- completer (c- ITT) 
analysis set, defined as all patients who were randomised and 
completed the treatment period; the per- protocol (PP) analysis 
set, defined as all patients in the c- ITT population without any 
major protocol deviations; and the safety (SAF) analysis set, 
defined as all patients who received at least part of the first infu-
sion of NI-0101 or placebo. Patients were analysed according to 
the actual treatment received.
Efficacy endpoints were analysed by statistical models including 
treatment, score for each measure at baseline and randomisa-
tion stratification factors (FcγRIIa genotype and CRP level at 
baseline) as fixed effect covariates. Other covariates, including 
country, duration of RA, use of non- steroidal anti- inflammatory 
drugs and glucocorticoids at baseline, baseline joint counts, ESR 
values, VECTRA DA scores and ACPA level could also be inves-
tigated in analyses of DAS28- CRP and ACR50 results.
Calculation of sample size for the randomised treatment arms 
was based on the change in DAS28- CRP between the NI-0101 
and the placebo groups for RR/RH population at week 12 
compared with predose. It was estimated that 54 RR/RH patients 
(NI-0101:placebo; 36:18) gave a power of 80% at a two- sided 
significance level of 5% assuming a difference in DAS28- CRP of 
1 point (SD=1.2) at 12 weeks between treatment and placebo 
(2:1 ratio). Considering that the population includes ≥66% of 
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Figure 1 Patient disposition. Data in boxes represent numbers of patients. *Defined as patients who received at least five of the six scheduled 
infusions and had at least one evaluable efficacy data at week 12.
RR/RH, the total number of patients required to complete the 
treatment was calculated to be 81 (NI-0101:placebo; 54:27) to 
ensure at least 54 RR/RH patients completed treatment. Ninety 
patients were randomised to compensate for dropouts.
RESULTS
Patients and screening phase
Of 250 patients screened for eligibility, 90 were randomised (61 
to NI-0101 and 29 to placebo group). All randomised patients 
received at least part of the first infusion of NI-0101 and 57 
completed the week 12 visit along with 29 patients treated with 
placebo, all of these patients completed the follow- up phase to 
week 24 (figure 1). Baseline demographic and disease charac-
teristics are summarised in table 1. There were no major imbal-
ances between groups for most individual disease parameters. 
However, patients in the NI-0101 group had a longer duration 
of RA (8.5 years vs 5.4 years for placebo) and were younger at 
the time of RA diagnosis (45.7 years vs 51.2 years for placebo). 
The mean CRP level was also higher for patients allocated to 
receive NI-0101 (18.3 mg/L vs 13.4 mg/L for placebo) at base-
line, whereas CRP levels at screening were slightly higher in the 
placebo group. CRP levels decreased between screening and 
baseline for most patients in each group, but the decline was 
greater for those who received placebo. Post hoc analysis demon-
strated that the magnitude of the CRP decrease was dependent 
on the recruitment site of origin.
Efficacy
Both treatment groups demonstrated similar decreases from 
baseline to week 12 in DAS28- CRP with no significant between- 
group difference (figure 2A); a similar pattern was observed for 
DAS28- ESR (figure 2B). CDAI and SDAI scores decreased by 
approximately 40% from baseline to week 12, again with no 
significant differences between treatment groups (figure 2C,D). 
The proportion of patients achieving EULAR responses (good 
or moderate) increased with treatment. By week 12, 27.6% and 
26.0% of patients in the placebo and NI-0101 groups, respec-
tively, had achieved EULAR good responses; and 55.2% and 
53.6% had achieved EULAR moderate responses (figure 3A). 
There were no significant between- group differences in ACR 
responses at week 12; 55.2% and 58.9% of patients in the 
placebo and NI-0101 groups, respectively, achieved ACR20 
responses; 20.7% and 14.3% achieved ACR50 responses, and 
10.3% and 10.7% achieved ACR70 responses (figure 3B–D). 
Swollen and tender joint counts also declined from baseline in 
both treatment groups. The changes in swollen joints from base-
line to week 12 were –6.1 and –7.1 for the placebo and NI-0101 
groups, respectively; and the respective values for tender joints 
were –6.3 and –8.1.
Subgroup analysis indicated no significant effects on stratifica-
tion by CRP and FcγRIIa genotype for DAS28- CRP or ACR50 
response. All subgroup analyses, based on levels of prespeci-
fied biomarkers (ACPA, RF, cFb- IC, anti- citrullinated protein/
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Table 1 Baseline demographic and clinical characteristics
Baseline 
characteristic Measure
Placebo, n (%) 
(n=29) 
NI-0101, n (%) 
(n=61) 
Sex, n (%) Males 6 (20.7) 11 (18.0)
Females 23 (79.3) 50 (82.0)
Race, n (%) White 29 (100.0) 61 (100.0)
Age (years) Mean (SD) 57.1 (13.07) 54.6 (11.10)
Median (range) 59.1 (20–79) 56.3 (23–76)
Weight (kg) Mean (SD) 68.8 (15.46) 71.4 (13.30)
Median (range) 66.5 (47.0–103.9) 70.8 (45.6–98.9)
BMI (kg/m²) Mean (SD) 25.2 (4.01) 26.3 (3.43)
Median (range) 25.9 (18.0–29.8) 26.3 (18.4–32.0)
Duration of RA Mean years (SD) 5.4 (4.82) 8.5 (7.86)
Range 0.5–17.1 0.5–33.1
Age at RA 
diagnosis
Mean years (SD) 51.2 (13.62) 45.7 (11.56)
Range 18–69 21–67
Steroid dose 
category
No steroid given 9 (31.0) 20 (32.8)
1–5 mg 8 (27.6) 6 (9.8)
5–10 mg 12 (41.4) 35 (57.4)
MTX dose 
category (mg/
week)
3.5–10 mg 2 (6.9) 2 (3.3)
10–20 mg 25 (86.2) 55 (90.2)
20–25 mg 2 (6.9) 4 (6.6)
CRP (mg/L) Mean (SD) 13.4 (14.03) 18.3 (26.63)
ESR (mm/hour) Mean (SD) 43.1 (16.51) 45.3 (24.26)
RF (IU/mL) Mean (SD) 127.6 (146.36) 149.3 (175.72)
ACPA (U/mL) Mean (SD) 962.6 (1730.87) 676.2 (1072.80)
DAS28- CRP Mean (SD) 5.8 (0.82) 5.9 (0.94)
DAS28- ESR Mean (SD) 6.6 (0.88) 6.6 (0.91)
68- tender joint 
counts
Mean (SD) 28.9 (14.07) 27.5 (15.89)
66- swollen joint 
counts
Mean (SD) 16.3 (7.92) 16.8 (8.96)
ACPA, anti- citrullinated protein antibody; BMI, body mass index; CRP, C reactive 
protein; DAS28, Disease Activity Score, including a 28- joint count; ESR, erythrocyte 
sedimentation rate; MTX, methotrexate; RA, rheumatoid arthritis; RF, rheumatoid 
factor.
Figure 2 (A) DAS28- CRP scores. (B) DAS28- ESR scores. (C) CDAI scores. (D) SDAI scores. All values are means±95% CI. Placebo, n=28; NI-0101, 
n=54. CDAI, Clinical Disease Activity Index ; DAS28- CRP, Disease Activity Score (28- joint count) with C reactive protein; AS28- ESR, Disease Activity 
Score (28- joint count) with erythrocyte sedimentation rate; SDAI, Simplified Disease Activity Index.
peptide antibodies, TLR4 ligands) measured at baseline and post 
hoc analyses using baseline disease- related parameters failed 
to demonstrate any significant treatment effects in any of the 
subgroups.
Pharmacokinetics
The NI-0101 pharmacokinetics (PK) profile showed expected 
concentrations with an elimination was consistent with simu-
lations. Throughout the treatment period, NI-0101 concentra-
tions were maintained above the targeted threshold of 10 000 ng/
mL in the majority of patients. The half- life for the linear elimi-
nation phase was estimated to be approximately 6.4 days.
Pharmacodynamics
There were no significant differences between treatment groups 
for all biomarkers evaluated (table 2). Analysis of changes in 
CRP levels from baseline to week 12 showed small increases for 
both treatment groups (see online supplementary data).
Safety
NI-0101 infusions every 2 weeks elicited an acceptable safety 
and tolerability profile in patients with RA. The Data Moni-
toring Committee did not request for changes in the conduct 
of the study and no deaths were reported. Treatment- emergent 
adverse events (TEAEs) reported from baseline to week 24 
occurred in similar proportions of patients in the placebo and 
NI-0101 groups; 51.7% and 52.5%, respectively (table 3). Five 
patients (5.6%) reported TEAEs considered to be related to 
NI-0101. One patient in the placebo group and three patients 
in the NI-0101 group discontinued treatment due to TEAEs; 
however, only one of these TEAEs (an infusion- related reaction 
(IRR)) was assessed as having a relationship with the administra-
tion of NI-0101. One patient in the placebo group experienced 
a serious adverse event (AE) (appendicitis and peritoneal abscess) 
as did three patients in the NI-0101 group (severe IRR, diagnosis 
of adenocarcinoma of the colon and diagnosis of ovarian cancer). 
In three other patients of the NI-0101 group, non- serious events 
(mild dermatitis, moderate urinary tract infection and alanine 
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Figure 3 (A) Percentage of patients achieving EULAR good or moderate responses. (B–D) Percentages of patients achieving ACR20, 50 and 70 
responses. ACR, American College of Rheumatology; EULAR, European League Against Rheumatism. Placebo, n=28; NI-0101, n=54. EULAR response 
at week 12: or 1.36, 95% CI (0.51; 3.67), p value 0.5381. ACR20 response at week 12: OR 1.07, 95% CI (0.42; 2.72), p value 0.8948. ACR50 response 
at week 12: OR 0.63, 95% CI (0.18; 2.18), p value 0.4665. ACR70 response at week 12: OR 0.94, 95% CI (0.20; 4.32), p value 0.9318.
Table 2 Assessments of inflammatory markers
Parameter, pg/mL
Baseline value, all patients, mean 
(SD)
Change from baseline to W12, mean (SD) P value
Placebo
(n=28)
Ni-0101
(n=54) Treatment effect Baseline value effect
CRP 15.6 (17.27) −0.3 (2.83) 0.6 (2.11) 0.7688 –
IL-6 19.3 (59.2) −5.3 (38.04) −2.4 (18.22) 0.3978 <0.0001
GM- CSF* 9.4 (0) 0 (0) 0 (0) – –
IL- 17A* 15.4 (0) 0 (0) 0 (0) – –
IL-10 0.8 (0.98) 0 (0.66) 0.3 (2.41) 0.5148 0.0319
IL-1β 1.2 (0.06) 0 (0) 0.1 (0.58) – <0.0001
IL-8 23.7 (18.87) 0.3 (12.24) −3.0 (15.73) 0.2698 <0.0001
INF-γ 15.5 (30.05) 7.5 (31.50) −0.2 (40.57) 0.7860 <0.0001
TNF-α 5.6 (11.99) 2.0 (11.49) −0.1 (1.85) 0.5548 <0.0001
CXCL10 651.9 (542.8) −17.4 (506.73) −35.7 (338.77) 0.5624 <0.0001
MCP-1 422.9 (162.18) 13.4 (127.29) −18.9 (124.58) 0.2667 0.0027
‘Baseline value effect’ assesses the effect of variability at baseline on the tested outcome. Here, baseline variability reported for the measured cytokines is higher than the tested 
treatment effect.
*Values were below limit of quantification.
CRP, C- reactive protein; CXCL10, C- X- C motif chemokine 10;GM- CSF, granulocyte- macrophage colony- stimulating factor; IL, interleukin; INF, interferon;IP-10, interferon gamma- 
induced protein 10; MCP, monocyte chemoattractant protein;TNF, tumour necrosis factor; W, week.
aminotransferase grade 2 increase) were reported as related to 
NI-0101 but did not result in treatment discontinuation.
Infections were the most frequently reported AEs (11.5% 
and 13.8% in the NI-0101 and placebo groups, respectively). 
None of the infections reported in the NI-0101 group were 
rated as severe or serious. Most were respiratory tract infections 
commonly observed during autumn and winter. All were mild 
or moderate in intensity. Infections were not considered related 
to study treatment, except one moderate urinary tract infection.
No safety signals were identified for other safety parameters.
DISCUSSION
This is the first study to assess the efficacy of TLR4 inhibition 
in patients with RA or indeed with an immune- mediated inflam-
matory disease. The efficacy analysis showed consistent, but 
moderate, improvements for all endpoints evaluated for both 
treatment groups but no significant differences between addi-
tion of NI-0101 or placebo to MTX. Response level observed in 
the placebo group was higher than typically reported for clinical 
studies in this population, particularly for moderate response 
measured either by EULAR criteria or by ACR20 response. 
Good EULAR responses and achievement of ACR50 and 
ACR70 improvements in the placebo group were closer to values 
reported previously for patients with inadequate responses to 
MTX and continued on this treatment, although on the high 
end of such response rates.32 33 In general, the NI-0101 treat-
ment group showed similar or worse responses than the placebo 
group at week 12. Moreover, the improvements noted were 
lower than observed when other targeted DMARDs (biologics 
or small molecules) have been added to therapy in MTX- IR 
patients with RA.34 35 Despite clinical improvement in both treat-
ment groups, there was no significant reduction from baseline 
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Table 3 TEAEs through 24 weeks
Placebo, n (%)
(n=29)
NI-0101, n (%)
(n=61)
Pretreatment AEs 1 (3.4) 2 (3.3)
TEAEs to week 24 15 (51.7) 32 (52.5)
TEAEs related to administered 
treatment
0 5 (8.2)
Serious TEAEs 1 (3.4) 3 (4.9)
TEAEs leading to treatment 
discontinuation
1 (3.4) 3 (4.9)
TEAEs leading to death 0 0
TEAEs related to potential IRRs 3 (10.3) 9 (14.8)
TEAEs related to infections 5 (17.2) 17 (27.9)
TEAEs by highest severity
  Mild 6 (20.7) 12 (19.7)
  Moderate 9 (31.0) 17 (27.9)
  Severe 0 3 (4.9)
  Life threatening 0 0
  Fatal 0 0
  Missing 0 0
TEAEs experienced by ≥5% of patients in either treatment group
Nasopharyngitis 2 (10.3) 3 (4.9)
Upper respiratory tract infection 1 (3.4) 4 (6.6)
Condition aggravated 0 5 (8.2)
IRRs, infusion- related reactions; TEAE, treatment emergent adverse event.
in CRP, an objective measure of inflammation, for patients 
receiving either placebo or NI-0101 added to MTX. A poten-
tial therapeutic response to MTX background therapy during 
screening was observed based on CRP decrease, possibly driven 
by higher adherence to background treatment between screening 
and randomisation.
The absence of a significant effect of adding NI-0101 to 
MTX was further confirmed by the lack of treatment- associated 
changes in levels of cytokines downstream from TLR4 and 
known to be involved in the inflammation characteristic of 
RA.36 The lack of effect of NI-0101 versus placebo on levels 
of inflammatory molecules evaluated in this study extended to 
IL-6, TNF-α, IL-8 and IL-1β, all of which have been shown to be 
elevated in monocytes from synovial fluid through TLR4 signal-
ling and blocked by exposure to NI-0101 in vitro.9 37
During the follow- up period, when the patient and treating 
physician knew that NI-0101 was no longer being administered 
(while remaining blinded to prior treatment allocation), the 
results for all efficacy endpoints remained stable or decreased 
by similar amounts in both treatment arms. As the elimination 
half- life of NI-0101 is 6.4 days, it would have been reasonable 
to expect some continued benefit after treatment withdrawal, if 
it had significant efficacy.
Preplanned subgroup analyses using baseline levels of TLR4- 
related biomarkers were conducted to test the hypothesis that RA 
patients with elevated levels of TLR4 ligands (eg, citrullinated 
protein immune complexes) would have an increased response 
to the addition of NI-0101 to MTX. However, patient segmen-
tation on the basis of the selected biomarkers failed to demon-
strate any benefit of NI-0101 versus placebo. Furthermore, post 
hoc subgroup analyses using baseline disease and demographic 
parameters, including, but not limited to, baseline CRP levels 
and variations during screening, country of origin and disease 
duration, were conducted to potentially identify confounding 
parameters, but none showed a statistically significant effect on 
any between- treatment differences. The PK results from this 
study and PK/pharmacodynamic analysis from a prior study31 
suggest that the levels of NI-0101 achieved in the patients in this 
trial were sufficient to achieve TLR4 pathway blockade between 
two dosing intervals, regardless of the FcγRIIa polymorphism. 
Thus, it is unlikely that insufficient levels of NI-0101 contrib-
uted to the observed lack of clinical effect.
Given that NI-0101 has been shown to be a potent inhibitor 
of TLR4, as demonstrated by the lack of induction of inflam-
matory cytokines after in vivo LPS administration in healthy 
volunteers after having received NI-0101 and that literature 
on pathogenic processes in RA reports the involvement of the 
stimulation of this receptor,7–12 31 the lack of significant clin-
ical and pharmacodynamic effects in this study are surprising. 
It is possible that redundancy in TLR signalling may underlie 
the lack of effect of TLR4 blockade in this trial. In fact, TLR2, 
TLR4, TLR5 and TLR7 have all been considered to be poten-
tially involved in the pathology of RA.38 It cannot be excluded 
that NI-0101 may provide clinical benefit when combined with 
other targeted agents. Indeed, the preclinical hypothesis tested 
in this study was supported by the observed correlation in vitro 
between NI-0101 response and the presence of specific immune 
complexes against citrullinated proteins.9 The presence of anti-
bodies against citrullinated proteins has been reported even 
before the first clinical manifestation of RA. It is conceivable, 
perhaps that immune complexes signalling through TLR4 could 
play a significant pathogenic role in early RA, whereas other 
inflammatory processes are predominant when RA is already 
established and therefore blocking TLR4 may not provide any 
benefit.
We demonstrate satisfactory safety and tolerability of TLR4 
inhibition with NI-0101. There were no significant differences 
between treatment groups in the frequency of AEs. The type 
and intensity of AEs reported in this study were similar to those 
observed in prior clinical trials in similar patient cohorts,39 40 and 
of the three serious AEs (IRR, adenocarcinoma of the colon and 
ovarian cancer) reported in the NI-0101 group, only the IRR 
was related to NI-0101 administration.
TLR4 has been shown to play an important role in immune 
response to Gram- negative bacteria.37 However, the results 
suggest no increased risk for infections with NI-0101 and are 
consistent with findings from healthy volunteers who received 
NI-0101, as well as those obtained with other molecules targeting 
the same pathways.31 41 42 No systemic Gram- negative infections 
were reported. The incidence of urinary tract infections (6.6%), 
all in female patients, appeared no greater than that reported for 
postmenopausal women who constitute the majority of the RA 
population.43 44
This study demonstrated that the blockage of TLR4 is likely 
not a relevant target in RA patients with inadequate response to 
MTX, as shown by the absence of NI-0101 effect versus placebo 
on clinical endpoints or on changes in levels of inflammatory 
cytokines or chemokines. In addition, none of the subgroup 
analyses identified a subset of patients that received benefit from 
NI-0101. The results showed an expected PK profile, desired 
concentrations and no safety concerns for NI-0101. The lack 
of significant effect of NI-0101 in this well- controlled prospec-
tive clinical trial indicates that blocking the TLR4 pathway alone 
is unlikely to benefit patients with established RA. The role 
of TLR4 and of anti- citrullinated antibodies forming immune 
complexes in prior diagnosis and in early RA remains to be estab-
lished. The good NI-0101 safety and PK profiles support further 
exploration in other diseases, in particular when microbial prod-
ucts are involved in inflammatory diseases or when high micro-
bial translocation is observed (eg, HIV).
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